Buoyed by the successful global marketing of its COVID-19 vaccines, Pfizer is teeing up to dominate the maternal vaccine market even as OB-GYNs on the front lines of maternal care sound the alarm about the COVID-19 shots’ infanticidal fallout.
On Nov. 1, Pfizer issued a press release about an investigational vaccine for pregnant women the company said will protect babies from respiratory syncytial virus (RSV).
Buoyed by the successful global marketing of its COVID-19 jabs — an estimated 49% of pregnant women worldwide reportedly views the vaccines favorably and almost 1 in 4 pregnant women in the U.S. took them — Pfizer is hoping to hit another home run with the RSV vaccine.
The vaccine maker said…
View original post 1,157 more words